IFNAR2 and COVID-19: Given that more than 10% of the COVID-19 diagnosed individuals requiring hospitalization reported migraine and headache symptoms44,45, reduced host expression of IFNAR2 may also modulate risk for migraine symptoms in the context of severe COVID-19 infection.